Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix Inc.

www.zogenix.com

Latest From Zogenix Inc.

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Performance Tracker Drug Review

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals

Stemline  Has What It Takes On EU Fast-Track Front  

There's good news for Stemline Therapeutics on the EU fast-track front. At least three other companies, though, have had their requests rejected in recent months and Novartis is not saying whether a request it made was successful or not.

Europe BioPharmaceutical

EU Accelerated Assessment Tracker: Second Half Trumps First By Far

The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.

Europe Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • SJ2 Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Zogenix Inc.
  • Senior Management
  • Stephen J Farr, PhD, Pres. & CEO
    Michael P Smith, EVP, CFO, Treasurer & Secretary
    Bradley S Galer, MD, EVP, CMO
    Gail M Farfel, PhD, EVP, Chief Dev. Officer
    Ashish Sagrolikar, EVP, Chief Commercial Officer
  • Contact Info
  • Zogenix Inc.
    Phone: (858) 259-1165
    5858 Horton St.
    Ste. 455
    Emeryville, CA 94608
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register